Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAIL66 in CLDN6-positive Solid Tumors
NCT05735366Phase 1Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Apr 2023
- Primary completion
- Jan 2026
- Modality
- Trispecific Antibodies, T-cell Engagers, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of SAIL66 in solid tumor (3 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoints: Adverse events of SAIL66 at 18 weeks, Change from baseline in vital signs at 18 weeks and 3 more. Started Apr 2023; status: completed.
02
Drugs
SAIL66
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05735366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05735366.